Real-world outcomes with adjuvant nonsteroidal aromatase inhibitors (NSAIs) vs tamoxifen (TAM) in patients with hormone receptor−positive/human epidermal growth factor receptor 2−negative (HR+/HER2−) early breast cancer (EBC): A US database analysis

2023

Graff SL, Tolaney SM, Hart LL, Razavi P, Fasching PA, Janni W, Schwartzberg LS, Lanoue B, Salas TR, Khakwani A, McDermott C, Pathak P, O'Shaughnessy J